BSE filing, NSE: AGARWALEYE. Summary written from the filing by ALFA Finder's alert engine.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹476.35
- Market cap
- ₹15,102 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 101.8×Sector 51.1×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Board Meeting Date
Dr. Agarwal's Health Care schedules a board meeting on November 5, 2026 to consider Q2 results. An earnings call follows at 6:30 PM IST that day.
Dr. Agarwals Health Care Merger & Restructuring Worth ₹711.2 Cr
Dr. Agarwals Health Care Limited has completed the merger of Dr. Agarwal's Eye Hospital Limited into itself for a total transaction value of ₹711.21 Crore.
- Value
- ₹711.2 Cr
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care Limited allotted 18,200 equity shares upon the exercise of vested ESOPs. The transaction is valued at approximately ₹0.24 Crore.
- Value
- ₹0.24 Cr
Dr. Agarwals Health Care Acquisition
The amalgamation scheme between Dr. Agarwal's Health Care and Dr. Agarwal's Eye Hospital is effective from November 01, 2026. The Record Date is November 18, 2026.
Dr. Agarwals Health Care Merger & Restructuring Worth ₹0.73 Cr
Dr. Agarwal's Health Care Ltd. completed the acquisition of its Nigeria-based step-down wholly owned subsidiary, previously announced on August 4, 2026, for ₹0.73 Crore.
- Value
- ₹0.73 Cr
Dr. Agarwals Health Care Merger & Restructuring
Dr. Agarwal's Health Care Limited confirmed that its step-down subsidiary, Orbit Healthcare Services Nigeria Ltd., is now a wholly owned subsidiary of Orbit Mauritius.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.